PI
ENTA icon

Pennant Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

Pennant Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,100
Closed -$455K – 27
2024
Q2 		$455K Hold
35,100
– – 0.12% 24
2024
Q1 		$613K Hold
35,100
– – 0.15% 20
2023
Q4 		$330K Buy
+35,100
New +$327K 0.07% 34

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pennant Investors's ENTA Position: Q3 2024 in Review

Pennant Investors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2024, closing a stake of 35,100 shares — an estimated $455K sold.

Pennant Investors first reported a position in ENTA in Q4 2023 and held it in 3 quarters. The position peaked at $613K in Q1 2024. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2024.

  • Pennant Investors reported no remaining Enanta Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 35,100 Enanta Pharmaceuticals shares in Q3 2024, an estimated $455K.
  • Pennant Investors first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Enanta Pharmaceuticals position peaked at $613K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.